Synaptogenix, Inc. - SNPX EV/EBITDA Multiple
Synaptogenix, Inc. (SNPX) is diversifying its risks by building a portfolio of small molecules to combat dementia. Its unique synapse restoration method could grant the firm monopoly pricing power over therapy costs. Current price action on GURU.Markets, based on the EV/EBITDA metric, is recorded at 0.00. Future business success will depend on clinical trial outcomes that sustain its R&D reputation among venture capitalists.
SNPX (synaptogen.com): analytical breakdowns and indicator data
- market price and analyst price targets:
- issuer market value details:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
SNPX - Net Financial Result|Future Profit Synaptogenix, Inc.|SNPX - Price to Earnings Multiple|Projected Price to Earnings Synaptogenix, Inc.|SNPX - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Synaptogenix, Inc|SNPX - Operating income before deduction of amortization|Earnings per share for the last twelve months Synaptogenix|SNPX - Earnings per share for the last 12 months|Quarterly EPS earnings growth synaptogen.com|SNPX - Net earnings per share growth this year|Expected earnings per share growth for next year Synaptogenix, Inc.
Basic company analysis:Neurotrope SNPX
Investors face a dilemma when determining the fair value of an asset amid volatile operating expenses. The EV/EBITDA multiple, accounting for net debt, links market capitalization and debt to pre-tax earnings, where a declining ratio signals undervaluation but warns of potential revenue declines. For Synaptogenix, Inc. (SNPX), this metric is critical as it reflects cost management efficiency when outsourcing clinical trials to third-party contractors.
Competitor analysis
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Corp BIIB|NBIX: Enterprise Value to Operating Income Before Depreciation|Regencell Bioscience - EV/EBITDA Multiple|AXSM - EV/EBITDA Multiple|ACADIA Pharmaceuticals Inc. (ACAD) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio XENE (Xenon Pharmaceuticals Inc.)|Enterprise Value to EBITDA Ratio VKTX|SUPN (Supernus Corp) - Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Catalyst Pharmaceuticals (CPRX)|DNLI - Company Value to EBITDA|EV/EBITDA Multiple HRMY (Harmony Biosciences Holdings, Inc.)|Enterprise Value to EBITDA Multiple Biohaven Ltd|Amylyx - EV/EBITDA Multiple|Company Value to EBITDA Trevi Corp|Praxis Precision Medicines (PRAX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation AVXL|CBLL (CeriBell) - EV/EBITDA Multiple|Prothena Corporation PLC (PRTA) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio ALEC (Alector, Inc.)|Annexon Biosciences Inc. - Enterprise Value to Operating Income Before Depreciation|Omeros - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation NGNE|AC Immune SA - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Voyager Therapeutics Inc VYGR|Neumora Therapeutics Inc (NMRA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation SCLX|TVGN (Tevogen Bio Holdings) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Alpha Cognition Corp (ACOG)|Enterprise Value to EBITDA Ratio CGTX (Cognition Therapeutics, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Inhibikase Therapeutics Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cassava SAVA|Total Company Value to Operating Income Before Depreciation Ratio Assertio Holdings (ASRT)|COYA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VTGN (Vistagen Therapeutics) - Enterprise Value to Operating Income Before Depreciation|ovidrx.com (OVID) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio ABOS (Acumen Pharmaceuticals Inc.)|Enterprise Value to EBITDA Ratio CRVO|Enterprise Value to Operating Income Before Depreciation ATHE (Alterity Therapeutics Ltd)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Clene Inc. (CLNN)|pepgen.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple JUNS (Jupiter Neurosciences)|Relmada Therapeutics Inc (RLMD) - Company Value to EBITDA|ANVS: Enterprise Value to EBITDA Ratio|GRCE - EV/EBITDA Multiple|Firefly Neuroscience, Inc (AIFF) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Klotho Neurosciences - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeuroSense Therapeutics Ltd|Company Value to EBITDA Reviva Pharmaceuticals Holdings Inc. RVPH|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MetaVia Inc (MTVA)|Total Company Value to Operating Income Before Depreciation Ratio NeurAxis Inc|Helius Medical Technologies - Enterprise Value to EBITDA Ratio|Passage Bio Inc. (PASG) - Company Value to EBITDA|NEUP - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NERV (Minerva Neurosciences Inc) - Enterprise Value to Operating Income Before Depreciation|ATHA: EV/EBITDA Multiple|Addex (ADXN) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alzamend Neuro Inc.|Cyclerion - Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio PTIX (Protagenic Therapeutics)|Enterprise Value to Operating Income Before Depreciation Ratio KTTA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cortigent CRGT|Avenue Therapeutics Inc (ATXI) - Company Value to EBITDA|Brainstorm Cell - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple caratherapeutics.com (CARA)|CHRO: EV/EBITDA Multiple|Company Value to EBITDA Eliem Therapeutics Inc. (ELYM)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Intra-Cellular Therapies Inc.|Enterprise Value to Operating Income Before Depreciation LBPH (Longboard)|EV/EBITDA Multiple MRNS|Total Company Value to Operating Income Before Depreciation Ratio nkgenbiotech.com|NeuroBo Pharmaceuticals, Inc. - Enterprise Value to EBITDA Ratio|SAGE: Enterprise Value to Operating Income Before Depreciation|TRVN: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation VIGL (Vigil Neuroscience)|WENA: EV/EBITDA Multiple|CERE - Total Company Value to Operating Income Before Depreciation Ratio
